Loading...
•
Dec 31, 2023
Vanda Q4 2023 Earnings Report
Vanda reported a net loss of $2.4 million and total revenues of $45.3 million, marking a 30% decrease in revenue compared to Q4 2022, but a 17% increase compared to Q3 2023. The company completed the acquisition of PONVORY® and is advancing its clinical development pipeline.
Key Takeaways
Vanda Pharmaceuticals reported a net loss of $2.4 million for Q4 2023, compared to a net income of $6.9 million in Q4 2022. Total revenues were $45.3 million, a 30% decrease from $64.5 million in Q4 2022, but a 17% increase compared to $38.8 million in Q3 2023. The company completed the acquisition of PONVORY® in Q4 2023 for $100 million.
Total net product sales were $45.3 million, a 30% decrease compared to Q4 2022.
HETLIOZ® net product sales were $21.1 million, a 47% decrease compared to Q4 2022, due to the at-risk launch of generic versions.
Fanapt® net product sales were $22.6 million, a 7% decrease compared to Q4 2022.
PONVORY® net product sales were $1.6 million, reflecting sales from December 7, 2023 to December 31, 2023, following its acquisition.
Revenue by Segment
Forward Guidance
Due to uncertainties surrounding the U.S. market for HETLIOZ® for the treatment of Non-24, Vanda is unable to provide 2024 financial guidance at this time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...